Dodge & Cox’s Corcept Therapeutics CORT Stock Holding History

Dodge & Cox’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,528	Closed	-$466K	–	193
2023 Q1	$466K	Buy	+21,528	New	+$472K	﹤0.01%	183

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Dodge & Cox's CORT Position: Q2 2023 in Review

Dodge & Cox sold out of Corcept Therapeutics (CORT) in Q2 2023, closing a stake of 21,528 shares — an estimated $466K sold.

Dodge & Cox first reported a position in CORT in Q1 2023 and held it in 1 quarter. The position peaked at $466K in Q1 2023. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

Dodge & Cox reported no remaining Corcept Therapeutics position as of Q2 2023 after selling out during the quarter.
Dodge & Cox sold 21,528 Corcept Therapeutics shares in Q2 2023, an estimated $466K.
Dodge & Cox first reported a position in Corcept Therapeutics in Q1 2023 and held it in 1 quarter.
Dodge & Cox's Corcept Therapeutics position peaked at $466K in Q1 2023.
224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on Dodge & Cox's 13F filing for Q2 2023, filed 14 Aug 2023.